Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Falanga

Showing results (11-20 of 241) with videos related to

Pageof 25
Sort By:
Haematologica|July 2, 2013
Circulating microparticles in children with sickle cell anemia: a heterogeneous procoagulant storm directed by hemolysis and fetal hemoglobinAnna Falanga, Alice Trinchero
Haematologica|December 18, 2023
Anticoagulation and thrombocytopenia in cancer: what more can we learn from existing randomized controlled trialsAnna Falanga, Cinzia Giaccherini
Pathophysiology of Haemostasis and Thrombosis|January 30, 2009
Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disordersMarina Marchetti, Anna Falanga
Thrombosis Research|April 13, 2016
Molecular biomarkers of thrombosis in myeloproliferative neoplasmsTiziano Barbui, Anna Falanga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Venous thromboembolism in the hematologic malignanciesAnna Falanga, Marina Marchetti
Seminars in Thrombosis and Hemostasis|March 11, 2014
Thrombosis in myeloproliferative neoplasmsAnna Falanga, Marina Marchetti
Hematology. American Society of Hematology. Education Program|December 13, 2012
Thrombotic disease in the myeloproliferative neoplasmsAnna Falanga, Marina Marchetti
Eksperimental'Naia Onkologiia|April 29, 2004
Venous thromboembolism in oncologyAnna Falanga, Alfonso Vignoli
Thrombosis Research|April 29, 2018
Hemostatic biomarkers in cancer progressionAnna Falanga, Marina Marchetti
Hematology. American Society of Hematology. Education Program|December 10, 2021
Evidence-Based Minireview: Are DOACs an alternative to vitamin K antagonists for treatment of venous thromboembolism in patients with MPN?Francesca Schieppati, Anna Falanga
Pageof 25

Showing results (11-20 of 241) with videos related to

Sort By:
Pageof 25
Haematologica|July 2, 2013
Circulating microparticles in children with sickle cell anemia: a heterogeneous procoagulant storm directed by hemolysis and fetal hemoglobinAnna Falanga, Alice Trinchero
Haematologica|December 18, 2023
Anticoagulation and thrombocytopenia in cancer: what more can we learn from existing randomized controlled trialsAnna Falanga, Cinzia Giaccherini
Pathophysiology of Haemostasis and Thrombosis|January 30, 2009
Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disordersMarina Marchetti, Anna Falanga
Thrombosis Research|April 13, 2016
Molecular biomarkers of thrombosis in myeloproliferative neoplasmsTiziano Barbui, Anna Falanga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Venous thromboembolism in the hematologic malignanciesAnna Falanga, Marina Marchetti
Seminars in Thrombosis and Hemostasis|March 11, 2014
Thrombosis in myeloproliferative neoplasmsAnna Falanga, Marina Marchetti
Hematology. American Society of Hematology. Education Program|December 13, 2012
Thrombotic disease in the myeloproliferative neoplasmsAnna Falanga, Marina Marchetti
Eksperimental'Naia Onkologiia|April 29, 2004
Venous thromboembolism in oncologyAnna Falanga, Alfonso Vignoli
Thrombosis Research|April 29, 2018
Hemostatic biomarkers in cancer progressionAnna Falanga, Marina Marchetti
Hematology. American Society of Hematology. Education Program|December 10, 2021
Evidence-Based Minireview: Are DOACs an alternative to vitamin K antagonists for treatment of venous thromboembolism in patients with MPN?Francesca Schieppati, Anna Falanga
Pageof 25